Presidio Property Trustの空売り状況は、投資家がPresidio Property Trustの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Presidio Property Trust (NASDAQ:SQFT) 株価情報, 空売り情報

Presidio Property Trust

Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.

Presidio Property Trust, Inc. - Class A Common Stock

Presidio Property Trust Inc

Presidio Property Trust, Inc. - 9.375% Series D Cumulative Redeemable Perpetual Preferred Stock, $0.01 par value per share

Presidio Property Trust, Inc. - Series A Common Stock Purchase Warrants

On May 28, 2025 (the "Closing Date"), our Avis Budget Rental Car Funding (AESOP) LLC subsidiary ("ABRCF") issued $736.5 million of asset-backed securities with a maturity of three years and five years, respectively, comprised of $199.0 million aggregate principal amount of Series 2025-1 4.80%, Class A notes, $29.75 million aggregate principal amount of Series 2025-1 5.24%, Class B notes, $21.25 million aggregate principal amount of Series 2025-1 5.87%, Class C notes and $33.29 million aggregate principal amount of Series 2025-1 7.48%, Class D notes, as well as $318.4 million aggregate principal amount of Series 2025-2 5.12%, Class A notes, $47.6 million aggregate principal amount of Series 2025-2 5.51%, Class B notes, $34.0 million aggregate principal amount of Series 2025-2 6.24%, Class C notes and $53.26 million aggregate principal amount of Series 2025-2 7.84%, Class D notes. The Class D notes were retained by ABRCF and may be sold on a future date. ABRCF also issued $15.6 million aggregate principal amount of Series 2025-1 9.424%, Class R notes and $25.0 million aggregate principal amount of Series 2025-2 9.795%, Class R notes, each of which are subordinated to the Class A notes, the Class B notes, the Class C notes and the Class D notes of the respective Series, and which were issued to comply with applicable U.S. risk retention rules. The Class R notes are held by our AESOP Leasing L.P. subsidiary. The notes were issued under the Series 2025-1 Supplement, dated as of the Closing Date, between ABRCF and The Bank of New York Mellon Trust Company, N.A., as trustee and Series 2025-1 Agent (the "Series 2025-1 Supplement"), to the Second Amended and Restated Base Indenture, dated as of June 3, 2004 (as amended, the "Base Indenture") and the Series 2025-2 Supplement, dated as of the Closing Date, between ABRCF and The Bank of New York Mellon Trust Company, N.A., as trustee and Series 2025-2 Agent (the "Series 2025-2 Supplement"), to the Base Indenture, respectively.

News

Financing

Avis Budget Rental Car Funding (AESOP) Issues $736.5M In Asset-Backed Securities Across Two Series With Maturities Of 3 And 5 Years

NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.01) by 7400 percent. This is a 76.92 percent increase over losses of $(3.25) per share from the same period last year.

Earnings

Earnings Misses

NCNA

NuCana Q1 EPADS $(0.75)

BSII

Black Spade Acquisition II To Voluntarily Delist From Nasdaq Upon Consummation Of Pending Business Combination With The Generation Essentials Group

Management

Donaldson Appoints Richard Lewis Chief Operating Officer, Effective August 1, 2025

Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) has outperformed the market over the past 10 years by 2.12% on an annualized basis producing an average annual return of 13.13%. Currently, Blackstone has a market capitalization of $107.39 billion. 
Buying $100 In BX: If an investor had bought $100 of BX stock 10 years ago, it would be worth $337.69 today based on a price of $138.92 for BX at the time of writing.
<h3>Blackstone's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748895316_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

Both Leading Proxy Advisory Firms Recommend Shareholders Vote AGAINST Chairman George Mayes, Jr., Director Javier Polit and Director Laurie Tucker
Glass Lewis Confirms That These Three Directors Are Unlikely to be "Procedurally Accretive" to the Ongoing Strategic Review
Ancora Holdings Group, LLC (together with its affiliates, "Ancora" or "we"), a significant shareholder of Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) ("Forward Air" or the "Company"), today announced that a second independent proxy advisory firm, Glass, Lewis &amp; Co. ("Glass Lewis"), has joined Institutional Shareholder Services Inc. ("ISS"), in recommending that Forward Air shareholders vote AGAINST the reelection of three members of the Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders: (1.) George S. Mayes, Jr., (2.) Javier Polit and (3.) Laurie A. Tucker.
In its report, Glass Lewis states the following regarding the case for removing these directors from the Board:1
<ul>
<li>"Are legacy directors who served during the questionable pursuit, fumbled execution and to-date maladroit implementation of the Omni deal credibly positioned to oversee Forward's current assessment of value-maximizing opportunities? We believe the answer is a firm no."</li>
<li>"[I]nvestors do not have clear and compelling cause to believe Messrs. Mayes and Polit and Ms. Tucker are likely to be procedurally accretive and indeed have ample cause to conclude they have not been effective in preserving and enhancing shareholder value, particularly in the context of transformative transactions."</li>
</ul>

FWRD

Both ISS And Glass Lewis Urge Forward Air Shareholders To Vote Against Chairman George Mayes Jr., Directors Javier Polit And Laurie Tucker, Citing Poor Oversight Of Omni Deal And Lack Of Value-Enhancing Contributions

BYFC

Broadway Financial Announces Nasdaq Noncompliance Notification

– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate –
– The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib –
– The combination was well-tolerated and demonstrated a safe and manageable toxicity profile –
SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced positive data from an investigator-initiated Phase 1b clinical trial evaluating onvansertib in combination with paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC) at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from May 30-June 3, 2025, in Chicago, Illinois.

CRDF

Cardiff Oncology Presents Data From Investigator-Initiated Phase 1b Clinical Trial Evaluating Onvansertib In Combination With Paclitaxel In Patients With mTNBC At 2025 ASCO Annual Meeting

ENSG

The Ensign Group Acquires Nursing Facility In California; Financial Terms Not Disclosed

Dividends

EPRT

Essential Properties Realty Trust Increases Quarterly Dividend From $0.295 To $0.30/Share

First-line maintenance combination therapy reduced the risk of disease progression or death by 46%, with a median overall survival of 13.2 months vs 10.6 months&nbsp;for atezolizumab alone from the point of randomization
First Phase 3 study to demonstrate statistically significant and clinically meaningful improvements in both progression-free and overall survival in ES-SCLC first-line maintenance
Results presented at the ASCO 2025 Annual Meeting and simultaneously published in The Lancet
Jazz to host investor webcast on Tuesday, June 10 to review Zepzelca data
For U.S. media and investors only
DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAZZ#NASDAQ">JAZZ</a>) today announced positive results from the Phase 3 IMforte study of Zepzelca&#xAE; (lurbinectedin) in combination with atezolizumab (Tecentriq&#xAE;) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and atezolizumab. The study met both primary endpoints, demonstrating statistically significant improvements in progression-free survival (PFS) and overall survival (OS) compared to atezolizumab alone.
IMforte is the first global Phase 3 trial to demonstrate clinically meaningful PFS and OS benefits in the first-line maintenance setting for ES-SCLC and supports maintenance therapy with Zepzelca&nbsp;plus atezolizumab as a new standard of care for patients. The data were presented today in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago and published simultaneously in <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4439716-1&amp;h=26984983&amp;u=https%3A%2F%2Fwww.thelancet.com%2Fjournals%2Flancet%2Farticle%2FPIIS0140-6736(25)01011-6%2Ffulltext&amp;a=The+Lancet">The Lancet</a>. Data from the trial served as the basis for the supplemental New Drug Application (sNDA) submission to the U.S. Food and Drug Administration&nbsp;(FDA).
Following induction therapy with carboplatin, etoposide and atezolizumab, patients who did not have disease progression were randomized to receive Zepzelca plus atezolizumab or atezolizumab alone. From the point of randomization, the median PFS was 5.4 months for the Zepzelca plus atezolizumab combination versus 2.1 months for atezolizumab alone (stratified HR = 0.54, 95% CI: 0.43–0.67; p &lt; 0.0001), and median OS was 13.2 months versus 10.6 months (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). The combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to atezolizumab alone. The Zepzelca plus atezolizumab combination had no new or unexpected safety signals.

Biotech

General

JAZZ

Jazz Pharmaceuticals Announces Phase 3 IMforte Trial Results Showing Zepzelca Plus Atezolizumab First-Line Maintenance Therapy Reduces Disease Progression Risk By 46% And Extends Median Overall Survival To 13.2 Months In ES-SCLC; Data Presented At ASCO 2025 And Published In The Lancet, Supporting New Standard Of Care And FDA sNDA Submission

Overall pan-cancer sensitivity of 94% and specificity of 100%, with analytical detection down to 1 PPM
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.natera.com&amp;esheet=54263860&amp;newsitemid=20250602831213&amp;lan=en-US&amp;anchor=Natera%2C+Inc.&amp;index=1&amp;md5=7205b90051b2da6a2abf789e99afd34b">Natera, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>), a global leader in cell-free DNA and precision medicine, announced results from a large-scale pan-cancer study of its Signatera Genome assay, which was presented today, June 2nd, at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
The study analyzed the performance of Signatera Genome in a cohort of 392 patients (&gt; 2,600 plasma samples) across five different tumor types (breast cancer, non-small cell lung cancer, melanoma, renal cell carcinoma, and colorectal cancer). Key results included:
<ul>
<li>Excellent pan-cancer performance: Signatera Genome demonstrated overall longitudinal sensitivity of 94% and specificity of 100% across 5 cancer types. Longitudinal sensitivity was 100% in lung cancer and renal cancer, and post-surgical landmark sensitivity was over 70% in both lung cancer and breast cancer.</li>
<li>Ultrasensitive detection: In the surveillance setting, nearly 50% of Signatera-positive cases were detected in the ultra-sensitive range (≤100 parts per million).</li>
<li>Highly predictive of long-term outcomes: In the pancancer cohort, patients who tested Signatera-negative had excellent prognosis, with 100% distant relapse-free survival (DRFS) at 12 months and 99% at 24 months. In contrast, Signatera-positive patients faced a markedly higher risk of recurrence, with DRFS dropping to 41% at 12 months and just 14% at 24 months.</li>
<li>Extended lead times: Signatera Genome detected recurrence 3 months earlier, on average, compared to the Signatera Exome assay.</li>
<li>Demonstrates Signatera's potential to identify which patients may benefit from adjuvant therapy: Among Signatera-positive patients, those who received adjuvant therapy had significantly improved outcomes, with a 12-month DRFS of 83% compared to 49% for those who did not receive therapy. For Signatera-negative patients, there was no meaningful benefit from adjuvant therapy with a 12-month DRFS of 93% (treated) vs. 98% (observation).</li>
</ul>

NTRA

Natera Presents Results From Large-Scale Pan-Cancer Study Of Signatera Genome Assay At 2025 ASCO Annual Meeting

Empowering enterprises across industries to build and deploy secure, compliant AI agents and applications with Snowflake Postgres, powered by Crunchy Data's enterprise-grade PostgreSQL
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.snowflake.com%2F&amp;esheet=54263223&amp;newsitemid=20250602455530&amp;lan=en-US&amp;anchor=Snowflake&amp;index=1&amp;md5=ba422637d7f8c26f397a956c82baaa6a">Snowflake</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>), the AI Data Cloud company, today announced at its annual user conference, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.snowflake.com%2Fen%2Fsummit%2F&amp;esheet=54263223&amp;newsitemid=20250602455530&amp;lan=en-US&amp;anchor=Snowflake+Summit+2025&amp;index=2&amp;md5=2df932361745e54fc8138426404cb066">Snowflake Summit 2025</a>, its intent to acquire Crunchy Data, a leading provider of trusted open source Postgres technology and products. This acquisition will bring Snowflake Postgres, the AI-ready, enterprise-grade and developer-friendly PostgreSQL database to the AI Data Cloud, enabling developers with the full power of Postgres while providing the uncompromising governance, security and operational standards essential for building and running mission-critical AI applications.

SNOW

Snowflake To Acquire Crunchy Data; Terms Undisclosed

VRSN

VeriSign Executive Vice President And Chief Financial Officer George E. Kilguss III Retired From The Company Effective May 31, 2025

First Quarter of Fiscal Year 2026 Financial Outlook
<ul>
<li>Revenue is expected to be between $185.0 million and $195.0 million</li>
<li>GAAP gross margin is expected to be between 63.4% and 65.4%, and non-GAAP gross margin is expected to be between 64.0% and 66.0%</li>
<li>GAAP operating expenses are expected to be between $88.3 million and $90.3 million, and non-GAAP operating expenses are expected to be between $54.0 million and $56.0 million</li>
</ul>

Guidance

CRDO

Credo Technology Group Sees Q1 Sales $185.000M-$195.000M vs $167.83M Est

Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.28 by 25 percent. This is a 400 percent increase over earnings of $0.07 per share from the same period last year. The company reported quarterly sales of $170.03 million which beat the analyst consensus estimate of $162.96 million by 4.34 percent. This is a 179.73 percent increase over sales of $60.78 million the same period last year.

Earnings Beats

Credo Technology Group Q4 Adj. EPS $0.35 Beats $0.28 Estimate, Sales $170.03M Beat $162.96M Estimate

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4440397-1&amp;h=3926069017&amp;u=https%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc">Trevi Therapeutics, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio&#x2122; (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and in patients with refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $100,000,000 of shares of its common stock. All of the shares in the offering are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase up to an additional $15,000,000 of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.

Offerings

TRVI

Trevi Therapeutics Launches $100M Public Offering Of Common Stock To Support Development Of Haduvio For Chronic Cough In IPF And RCC

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.personalis.com%2F&amp;esheet=54263877&amp;newsitemid=20250602947359&amp;lan=en-US&amp;anchor=Personalis%2C+Inc.&amp;index=1&amp;md5=3e4c9e0b952c4b9b34435ce78c8a2a75">Personalis, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (TNBC), one of the most aggressive types of breast cancer.
Results from the PREDICT DNA study were presented yesterday by Dr. Natasha Hunter, MD, University of Washington, at the American Society for Clinical Oncology (ASCO) 2025 Annual Meeting in Chicago in an oral presentation titled "Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT DNA trial)."
Key findings included:
ctDNA status after completion of NAT (post-NAT) was highly prognostic for relapse-free survival (RFS). Patients with ctDNA detected post-NAT were ~10 times more likely to relapse than patients who were ctDNA negative. Detection of ctDNA post-NAT was more predictive of recurrence than pCR. Patients who did not have detectable post-NAT ctDNA had excellent outcomes regardless of pathologic response. Preliminary analyses indicate that patients who had post-surgical ctDNA detected were &gt;85 times more likely to experience disease recurrence. 48% of post-NAT ctDNA detections were &lt;100 PPM, highlighting the importance of NeXT Personal's ultrasensitive performance. Overall, the results suggest that ultrasensitive ctDNA detection in patients with TNBC after completion of NAT and prior to surgery may be used as a prognostic marker, independent of pCR, to guide clinical decision making for additional adjuvant therapies.
 &nbsp;

PSNL

Personalis Presents New Clinical Results From PREDICT DNA And SCANDARE Studies Highlighting Capabilities Of Ultrasensitive NeXT Personal ctDNA Blood Test For Monitoring And Predicting NAT Response In TNBC

4 analysts have shared their evaluations of Rollins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROL#NYSE">ROL</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Rollins and provided 12-month price targets. The average target is $58.0, accompanied by a high estimate of $65.00 and a low estimate of $50.00. This upward trend is evident, with the current average reflecting a 12.62% increase from the previous average price target of $51.50.
<img src="https://www.benzinga.com/files/images/story/2025/1748894487_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Rollins. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephanie Moore</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Brian McNamara</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Hold</td>
<td>$50.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Ashish Sabadra</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$55.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Rollins. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Rollins compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Rollins's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Rollins's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ROL/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rollins analyst ratings.</a>
<h2>Discovering Rollins: A Closer Look</h2>
Rollins is a global leader in route-based pest control services, with operations primarily in the United States, as well as in North, Central, and South America, Europe, the Middle East, Africa, and Australia. Its portfolio of pest-control brands includes the prominent Orkin brand, a market leader in the US, which boasts near national coverage, and in Canada. Residential pest and termite prevention dominates the services provided by Rollins, owing to the group's ongoing focus on the US and Canadian markets.
<h3>Key Indicators: Rollins's Financial Health</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Rollins's remarkable performance in 3M is evident. As of 31 March, 2025, the company achieved an impressive revenue growth rate of 9.91%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Rollins's net margin excels beyond industry benchmarks, reaching 12.8%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.84%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Rollins's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.65% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Rollins's debt-to-equity ratio is below the industry average at 0.67, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Rollins Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

Providing a diverse range of perspectives from bullish to bearish, 16 analysts have published ratings on Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) in the last three months.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">8</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $152.0, a high estimate of $185.00, and a low estimate of $115.00. Highlighting a 1.89% decrease, the current average has fallen from the previous average price target of $154.93. 
<img src="https://www.benzinga.com/files/images/story/2025/1748894478_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Neurocrine Biosciences by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$154.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$165.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$115.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$152.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$158.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$139.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$158.00</td>
<td>$163.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$168.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Announces</td>
<td>Buy</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$137.00</td>
<td>$138.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$137.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$184.00</td>
<td>$183.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$150.00</td>
<td>$185.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Neurocrine Biosciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Neurocrine Biosciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Neurocrine Biosciences's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Discovering Neurocrine Biosciences: A Closer Look</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>A Deep Dive into Neurocrine Biosciences's Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 11.12%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Neurocrine Biosciences's net margin is impressive, surpassing industry averages. With a net margin of 1.38%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 0.31%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.21%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.18, Neurocrine Biosciences adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NBIX

Analyst Expectations For Neurocrine Biosciences's Future

Press Releases

Presidio Property Trust Provides Update on Model Home Activity in Q4 2024

Presidio Property Trust Announces Sales of Union Town Center and Research Parkway Properties

Presidio Property Trust Provides Update on Real Estate Activity in January and February 2025

Real Estate

Presidio Property Trust, Inc. Announces Earnings for the Year Ended December 31, 2024

Presidio Property Trust Announces Series D Preferred Stock Cash Dividend

CORRECTION – Presidio Property Trust, Inc. Announces Earnings for the Year Ended December 31, 2024

Presidio Property Trust Commences a Tender Offer to Repurchase up to 2,000,000 shares, plus all odd lots, of its Series A Common Stock

Presidio Property Trust, Inc. Announces Final Results of Its Self Tender Offer for Shares of Class A Common Stock

Presidio Property Trust, Inc. Announces Earnings for the Three Months Ended March 31, 2025

Markets

Presidio Property Trust Announces Reverse Stock Split

SQFT

SQFTP

SQFTW

American Assets Trust

Armada Hoffler Properties, Inc. Common Stock

Armada Hoffler Properties

Alexander & Baldwin, Inc. Common Stock REIT Holding Company

Alexander & Baldwin

Broadstone Net Lease

CTO Realty Growth

Essential Properties Realty Trust, Inc. Common Stock

Essential Properties

Empire State Realty OP, L.P. Series ES Operating Partnership Units Representing Limited Partnership Interests

Empire State Realty OP

Generation Income Properties Inc. - Common stock

Generation Income

Global Net Lease

Gladstone Commercial Corporation - Real Estate Investment Trust

Gladstone Commercial

Modiv Industrial, Inc. Class C Common Stock

Modiv Industrial

MacKenzie Realty Capital, Inc. - Common Stock

Mackenzie Realty Capital

NexPoint Diversified Real Estate Trust Common Stock

NexPoint Diversified Real

One Liberty Properties, Inc. Common Stock

One Liberty Properties

Alpine Income Property Trust, Inc. Common Stock

Comments

Presidio Property Trust

空売り

Presidio Property Trust (NASDAQ:SQFT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル